Article Text

other Versions

PDF

Correspondence
Answer to ‘COPD and IPF: it's all about regulation and balance’
  1. Jia Hou1,2,
  2. Yongchang Sun1,
  3. Hui Zeng3
  1. 1Department of Respiratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China
  2. 2Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, China
  3. 3Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
  1. Correspondence to Professor Yongchang Sun, Department of Respiratory Medicine, Beijing Tongren Hospital, Capital Medical University, No. 1 Dongjiaominxiang, Dongcheng District, Beijing 100730, China; suny{at}ccmu.edu.cn and Professor Hui Zeng, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Jingshundongjie 8, Beijing 100015, China; zenghui{at}ccmu.edu.cn

Statistics from Altmetric.com

We thank Tzouvelekis and Bouros1 for their interest in our recent article in Thorax.2 The theory of Hippocrates reminds us of the balance theory informing traditional Chinese medicine. Ancient Chinese scholars believed there were two natural, complementary yet contradictory forces in our universe: yin and yang, with the former being feminine or negative and the latter masculine or positive. Both of them are always in a state of dynamic balance. A balanced state of yin and yang means health whereas an excess or deficiency of one or the other usually indicates disease. Ancient scholars in China therefore treated this phenomenon as the universal law. The delicate balance of anti-inflammatory (yang) or proinflammatory (yin) power plays a pivotal role in maintaining lung homeostasis.3 Based on our findings and previous studies, we believe that this imbalance exists in COPD and idiopathic pulmonary fibrosis (IPF) and in other immune-mediated disorders.

According to the theory of yin and yang, the main goal of medical therapy was to restore the delicate balance. Glucocorticoids are the most effective anti-inflammatory treatments available for many inflammatory and immune diseases, including asthma, rheumatoid arthritis, inflammatory bowel disease and autoimmune diseases. Glucocorticoids inhibit the activation and proliferation of inflammatory cells by chromatin remodelling and gene expression. On the other hand, glucocorticoid treatment promotes or initiates differentiation of CD4 T cells to regulatory T (Treg) cells by a FOXP3-dependent mechanism.4 It seems that glucocorticoids are trying to restore the homeostasis between inflammatory and regulatory cells. However, no effect of glucocorticoids on the number of Tregs in patients with IPF5 and COPD2 was reported, probably due to the glucocorticoid resistance characterising these two diseases. Anyway, further studies are still needed to clarify whether glucocorticoids or other immunomodulating agents have any effects on the different subpopulations of Treg cells in COPD or IPF. Finally, we agree with Tzouvelekis and Bouros that an exploration of the Treg profiles in combined pulmonary fibrosis and emphysema is of great importance, as it could contribute to our understanding of adaptive immunity in the pathogenesis of both diseases.

References

View Abstract

Footnotes

  • Contributors JH, YS and HZ drafted the manuscript which was amended and finally approved by YS and HZ.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles